Zymeworks (NASDAQ:ZYME), a clinical-stage biotechnology company developing multifunctional biotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZW191 for the treatment of patients with advanced or metastatic platinum-resistant ovarian cancer (PROC).
The announcement, made on March 30, 2026, underscores the urgent clinical need for more effective therapeutic options for patients who have progressed on standard platinum-based chemotherapy.
ZW191 is a potential best-in-class antibody-drug conjugate (ADC) designed to target folate receptor-alpha (FRα), a protein that is highly expressed in several difficult-to-treat solid tumors.
Current clinical data suggests that FRα is present in approximately 75% of high-grade serous ovarian carcinomas, more than 50% of endometrial cancers, and nearly 70% of lung adenocarcinomas.
By utilizing a proprietary topoisomerase-1 (TOPO1) inhibitor payload and a stable, cleavable linker, ZW191 is engineered to deliver potent cytotoxic activity directly to tumor cells while minimizing off-target toxicity.
The candidate is currently being evaluated in an ongoing global Phase 1 clinical trial (NCT06555744).
The study is designed to assess the safety, tolerability, and pharmacokinetics of ZW191, alongside preliminary anti-tumor activity in patients with FRα-expressing cancers.
The Fast Track designation will allow Zymeworks to engage in more frequent communication with the FDA and potentially qualify for Accelerated Approval and Priority Review, provided relevant criteria are met.